Tatva Chintan Pharma Chem Limited Stock Price Today (NSE: TATVA)
Fundamental Score
Tatva Chintan Pharma Chem Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Tatva Chintan Pharma Chem Limited share price today is ₹1193.50, up +0.64% on NSE/BSE as of 17 June 2026. Tatva Chintan Pharma Chem Limited (TATVA) is a Small-cap company in the Specialty Chemicals sector with a market capitalisation of ₹3.37K (Cr). The 52-week high for TATVA share price is ₹1610.00 and the 52-week low is ₹886.00. At a P/E ratio of 189.69x, TATVA is currently trading above its industry average P/E of 29.20x. The company has a Return on Equity (ROE) of 0.78% and a debt-to-equity ratio of 0.11.
Tatva Chintan Pharma Chem Limited Share Price Chart — NSE/BSE Historical Performance
Tatva Chintan Pharma Chem Limited share price chart: -13.57% return over the past month. 52-week high ₹1610.00, 52-week low ₹886.00.
Tatva Chintan Pharma Chem Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1177.90 | ₹1225.00 | ₹1175.80 | ₹1214.40 | 38.40K (Cr) | |
| ₹1138.00 | ₹1219.20 | ₹1138.00 | ₹1195.50 | 1.18L (Cr) | |
| ₹1146.80 | ₹1171.80 | ₹1107.10 | ₹1133.20 | 1.27L (Cr) | |
| ₹1151.00 | ₹1165.30 | ₹1140.80 | ₹1146.80 | 43.18K (Cr) | |
| ₹1187.90 | ₹1201.00 | ₹1155.50 | ₹1158.00 | 38.74K (Cr) | |
| ₹1187.50 | ₹1208.10 | ₹1176.00 | ₹1182.70 | 34.96K (Cr) | |
| ₹1192.40 | ₹1203.00 | ₹1174.50 | ₹1187.50 | 35.38K (Cr) | |
| ₹1249.90 | ₹1263.40 | ₹1179.10 | ₹1187.70 | 92.17K (Cr) | |
| ₹1278.50 | ₹1289.80 | ₹1236.00 | ₹1241.90 | 46.27K (Cr) | |
| ₹1260.00 | ₹1315.00 | ₹1255.10 | ₹1282.40 | 51.53K (Cr) |
Tatva Chintan Pharma Chem Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1138.00 | ₹1225.00 | ₹1138.00 | ₹1214.40 | +6.71% | |
| ₹1310.00 | ₹1420.00 | ₹1107.10 | ₹1133.20 | -13.50% | |
| ₹1050.00 | ₹1356.00 | ₹1050.00 | ₹1311.00 | +24.86% | |
| ₹1156.80 | ₹1250.90 | ₹1044.10 | ₹1052.40 | -9.02% | |
| ₹1090.20 | ₹1291.90 | ₹1077.00 | ₹1223.50 | +12.23% | |
| ₹1333.00 | ₹1494.40 | ₹1100.80 | ₹1154.20 | -13.41% | |
| ₹1467.10 | ₹1515.00 | ₹1286.00 | ₹1334.20 | -9.06% | |
| ₹1455.00 | ₹1610.00 | ₹1365.00 | ₹1457.10 | +0.14% | |
| ₹1010.10 | ₹1447.40 | ₹1003.00 | ₹1422.30 | +40.81% | |
| ₹1045.50 | ₹1149.00 | ₹976.40 | ₹1011.90 | -3.21% | |
| ₹1181.00 | ₹1188.00 | ₹1010.10 | ₹1040.30 | -11.91% | |
| ₹959.60 | ₹1232.75 | ₹919.75 | ₹1167.00 | +21.61% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Tatva Chintan Pharma Chem Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Tatva Chintan Pharma Chem Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of TATVA across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Strong Operating Margins (17.54%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (1603.03%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (47.95%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.11)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (15.20x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (72.02%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Below-Average Return on Equity (0.78%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (1.20%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 189.69x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Weak Earnings Growth (-44.61% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-31.41% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Negative Free Cash Flow (₹-327.00 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 7.27%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Tatva Chintan Pharma Chem Limited vs Specialty Chemicals Peers
Peer Comparison - Specialty Chemicals
Compare Tatva Chintan Pharma Chem Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
37.5/100 | ₹1193.50₹1194 | ₹3365.02₹3365.02 | 189.69Average 189.7 Average | 0.78%Poor 0.78% Poor | 1.20%Poor 1.20% Poor | 0.11Excellent 0.1 Excellent | -31.41%Poor -31.41% Poor | 7.77%Good 7.77% Good | 0.07% | |
Pidilite Industries LimitedPidilite Indust... PIDILITIND • 500331 | 60.4/100 | ₹1480.70₹1481 | ₹149466.57₹149466.57 | 66.59Average 66.6 Average | 23.05%Excellent 23.05% Excellent | 29.84%Excellent 29.84% Excellent | 0.05Excellent 0.1 Excellent | 12.63%Good 12.63% Good | 12.49%Good 12.49% Good | 0.68% |
Gujarat Fluorochemicals LtdGujarat Fluoroc... FLUOROCHEM • 542812 | 51.5/100 | ₹3682.10₹3682 | ₹37241.99₹37241.99 | 54.77Average 54.8 Average | 8.29%Poor 8.29% Poor | 9.89%Poor 9.89% Poor | 0.23Excellent 0.2 Excellent | 21.05%Excellent 21.05% Excellent | 12.69%Good 12.69% Good | 0.09% |
Navin Fluorine International LtdNavin Fluorine ... NAVINFLUOR • 532504 | 40.6/100 | ₹7244.50₹7245 | ₹29462.02₹29462.02 | 66.34Average 66.3 Average | 11.52%Average 11.52% Average | 11.68%Average 11.68% Average | 0.33Excellent 0.3 Excellent | -6.59%Poor -6.59% Poor | 17.22%Excellent 17.22% Excellent | 0.21% |
Deepak Nitrite LtdDeepak Nitrite ... DEEPAKNTR • 506401 | 40.2/100 | ₹1714.80₹1715 | ₹21083.64₹21083.64 | 39.67Average 39.7 Average | 13.36%Average 13.36% Average | 16.28%Good 16.28% Good | 0.23Excellent 0.2 Excellent | 2.02%Average 2.02% Average | 14.38%Good 14.38% Good | 0.49% |
BASF India LtdBASF India Ltd... BASF • 500042 | 52/100 | ₹3430.20₹3430 | ₹17807.40₹17807.40 | 46.29Average 46.3 Average | 13.73%Average 13.73% Average | 18.02%Good 18.02% Good | 0.04Excellent 0.0 Excellent | 57.98%Excellent 57.98% Excellent | 14.83%Good 14.83% Good | 0.49% |
Atul LtdAtul Ltd... ATUL • 500027 | 50.5/100 | ₹7002.50₹7003 | ₹17066.13₹17066.13 | 31.47Average 31.5 Average | 9.10%Poor 9.10% Poor | 12.81%Average 12.81% Average | 0.03Excellent 0.0 Excellent | -5.82%Poor -5.82% Poor | 6.41%Good 6.41% Good | 0.43% |
Vinati Organics LtdVinati Organics... VINATIORGA • 524200 | 57.2/100 | ₹1325.10₹1325 | ₹16256.72₹16256.72 | 34.97Average 35.0 Average | 15.75%Good 15.75% Good | 20.61%Excellent 20.61% Excellent | 0.00Excellent 0.0 Excellent | 4.46%Average 4.46% Average | 16.92%Excellent 16.92% Excellent | 0.48% |
Anupam Rasayan India LtdAnupam Rasayan ... ANURAS • 543275 | 37.5/100 | ₹1368.00₹1368 | ₹14036.52₹14036.52 | 92.84Average 92.8 Average | 3.32%Poor 3.32% Poor | 7.33%Poor 7.33% Poor | 0.38Excellent 0.4 Excellent | 11.97%Good 11.97% Good | 22.13%Excellent 22.13% Excellent | 0.06% |
Aarti Industries LtdAarti Industrie... AARTIIND • 524208 | 41.9/100 | ₹500.75₹501 | ₹13796.68₹13796.68 | 51.29Average 51.3 Average | 6.03%Poor 6.03% Poor | 6.32%Poor 6.32% Poor | 0.70Good 0.7 Good | -9.09%Poor -9.09% Poor | 11.68%Good 11.68% Good | 0.26% |
Fine Organic Industries LtdFine Organic In... FINEORG • 541557 | 60.5/100 | ₹4677.30₹4677 | ₹13359.76₹13359.76 | 33.38Average 33.4 Average | 19.47%Good 19.47% Good | 26.39%Excellent 26.39% Excellent | 0.01Excellent 0.0 Excellent | 20.04%Excellent 20.04% Excellent | 16.93%Excellent 16.93% Excellent | 0.25% |
Top Specialty Chemicals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Pidilite Industries Limited share price149466.57 Cr
- Gujarat Fluorochemicals Ltd share price37241.99 Cr
- Navin Fluorine International Ltd share price29462.02 Cr
- Deepak Nitrite Ltd share price21083.64 Cr
- BASF India Ltd share price17807.40 Cr
Tatva Chintan Pharma Chem Limited PE Ratio History
Historical price-to-earnings ratio for TATVA — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹2.44 | ₹1334.20 | 546.8x |
| FY 2024 | ₹13.26 | ₹889.50 | 67.1x |
| FY 2023 | ₹20.52 | ₹1601.80 | 78.1x |
| FY 2022 | ₹44.59 | ₹2150.65 | 48.2x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Tatva Chintan Pharma Chem Limited Dividend History
Annual cash dividends paid by TATVA — dividend yield 0.07%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹4.68 Cr |
| FY 2024 | ₹4.68 Cr |
| FY 2023 | ₹4.43 Cr |
| FY 2021 | ₹4.02 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Tatva Chintan Pharma Chem Limited Quarterly Performance
Latest quarterly metrics for TATVA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
47.95%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
1603.03%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
7.77%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-31.41%
Compounded annual net profit growth over 5 years
Tatva Chintan Pharma Chem Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for TATVA — calculated from daily price history
Selling pressure is heavy — potential reversal zone.
Technical indicators are for educational purposes only. Not investment advice.
Tatva Chintan Pharma Chem Limited Financial Statements
Annual income statement, balance sheet and cash flow for Tatva Chintan Pharma Chem Limited (TATVA) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Tatva Chintan Pharma Chem Limited
About TATVA (Tatva Chintan Pharma Chem Limited)
Tatva Chintan Pharma Chem Limited is a prominent figure in the realm of specialty chemicals, carving a niche for itself through the development and production of high-value, applic...ation-specific chemicals. Their operations span a diverse portfolio, showcasing expertise in complex chemical synthesis and process optimization. Tatva Chintan distinguishes itself by offering tailored solutions, often working closely with clients to meet exacting specifications. These solutions are instrumental in enhancing the performance and properties of end products across various industries. The company's strength lies in its focus on research and development, enabling it to continually innovate and offer advanced chemical solutions, thereby solidifying its competitive edge in the global market. Tatva Chintan's product range is characterized by its specialization, encompassing structure directing agents (SDAs), vital for the synthesis of zeolites and molecular sieves. They also manufacture phase transfer catalysts (PTCs), essential for facilitating reactions between immiscible substances. Furthermore, they are involved in the production of electrolyte salts for supercapacitor batteries, contributing to the burgeoning energy storage sector. Beyond these, the company boasts a robust catalog of pharmaceutical and agrochemical intermediates, alongside other specialty chemicals tailored for specific applications. This diverse product offering, coupled with rigorous quality control measures, positions Tatva Chintan as a reliable supplier to a wide array of industries demanding high-purity and performance-driven chemical solutions. With a footprint that extends beyond India, Tatva Chintan operates in key global markets, including Germany, the United States, China, and Singapore, reflecting its international ambitions and capabilities. They cater to a diverse clientele across industries such as automotive, refinery, pharmaceuticals, and agrochemicals, demonstrating the broad applicability of their specialized chemicals. This widespread reach is supported by a strong emphasis on customer service and technical support, ensuring that clients receive the optimal solutions for their needs. Tatva Chintan's commitment to sustainability and responsible manufacturing practices further strengthens its reputation as a forward-thinking and ethically conscious player in the specialty chemicals arena.
Company Details
Key Leadership
TATVA Share Price: Frequently Asked Questions
What is the current share price of Tatva Chintan Pharma Chem Limited?
Tatva Chintan Pharma Chem Limited (TATVA) trades at ₹1193.50 on NSE and BSE. Market cap ₹3.37K (Cr). Educational data only.
What is the P/E ratio of Tatva Chintan Pharma Chem Limited?
Tatva Chintan Pharma Chem Limited has a P/E of 189.69x vs industry average 29.20x.
What is the Bull Run score for Tatva Chintan Pharma Chem Limited?
Tatva Chintan Pharma Chem Limited has a Bull Run score of 37.5/100 based on 25+ financial parameters.
Does Tatva Chintan Pharma Chem Limited pay dividends?
Tatva Chintan Pharma Chem Limited has a dividend yield of 0.07%. Past dividends don't guarantee future payments.
What is the ROE of Tatva Chintan Pharma Chem Limited?
Tatva Chintan Pharma Chem Limited has ROE of 0.78%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Tatva Chintan Pharma Chem Limited?
Tatva Chintan Pharma Chem Limited has debt-to-equity of 0.11.
Is Tatva Chintan Pharma Chem Limited a good investment?
Bull Run gives Tatva Chintan Pharma Chem Limited a score of 37.5/100. This is not investment advice — consult a SEBI-registered advisor.